



# GAGNANTS DE LA BOURSE DE RECHERCHE ALDO DEL COL

## 2022

- **Can BCMA trogocytosis compromise the anti-tumour activity of CAR-NK cells?**  
Dre Alissa Visram, Ottawa Hospital Research Institute, Ottawa (Ontario)
- **A novel eHealth application to support exercise prehabilitation prior to stem cell transplantation**  
Margaret McNeely, PhD; Cross Cancer Institute, Edmonton (Alberta)

**Comité d'examen:** Dre Sarit Assouline; Dr Andrew Belch; Beverly Dawson; Dre Nicole Laferriere; Dre Wendy Lam; Robin Sully

## 2023

- **Creating nanobody bispecific engagers for the treatment of myeloma**  
Scott McComb, PhD; University of Ottawa, National Research Council Canada, Ottawa (Ontario)
- **Targeting PIKfyve for the treatment of myeloma**  
Dr Keith Stewart & Cecilia Bonolo de Campos, PhD; University Health Network  
Princess Margaret Cancer Centre, Toronto (Ontario)
- **Defining the origin and metabolic pathways of osteoclasts in myeloma**  
Dr Florian Kuchenbauer, Terry Fox Laboratory, BC Cancer, Vancouver (Colombie Britannique)
- **Understanding the biology and outcome of young myeloma patients treated with modern therapies in Canada**  
Dr Jean Roy, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal (Québec)

**Comité d'examen:** Dre Sarit Assouline; Dr Andrew Belch; Marie-Eve Laforest, PhD, RN; David McMullen; Dre Nicole Laferriere; Dre Wendy Lam; Dre Martha Louzada;

## 2024

- **GMP virus production for first-in-human cell therapy trial (the TACTful study)**  
Jonathan Bramson, PhD; McMaster University, Hamilton (Ontario)
- **Correlative study: Fixed duration vs continuous daratumumab in newly diagnosed patients with myeloma (CCTG MY13 trial)**  
Dre Hira Mian, McMaster University, Hamilton (Ontario)
- **Prospective assessment of peripheral blood M-proteins using Mass-Fix to de-escalate therapy**  
Dr Jean-Sébastien Claveau, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal (Québec)
- **How to best arm a killer: Analysis of NK cell responsiveness in myeloma patients for rationale design of bi-specific antibodies**  
Michele Ardolino, PhD; University of Ottawa, Ottawa Hospital Research Institute, Ottawa (Ontario)

**Comité d'examen:** Dre Versha Banerji; Philip Barker, PhD; Dr Andrew Belch; Dre Gurbakhash Kaur; Marie-Eve Laforest, PhD, RN; Dre Martha Louzada; David McMullen; Vijay Ramakrishnan, PhD;



## 2025

- **TRAIL armoured anti-BCMA CAR T-cells in MM**  
Dr Nizar Bahlis, University of Calgary, Calgary (Alberta)
- **Creating, characterizing, and testing non-BCMA TCE and NKCE immunotherapies**  
Scott McComb, PhD; National Research Council of Canada, Ottawa (Ontario)
- **A phase II study of finite duration anti-BCMAxCD3 bispecific antibody therapy guided by PRD using clonotypic MS (EasyM) in patients with RRMM**  
Dre Suzanne Trudel, University of Toronto, Toronto (Ontario)
- **High sensitivity MM assessment in peripheral blood: Development of an innovative monitoring platform**  
Dr Richard LeBlanc, Université de Montréal, Montreal (Quebec)

**Comité d'examen:** Dre Versha Banerji; Philip Barker, PhD; Dr Andrew Belch; Dre Sita Bhella; Dre Gurbakhash Kaur; Marie-Eve Laforest, PhD, RN; Arvind Mer, MTech, PhD; Dre Charlotte Pawlyn; Vijay Ramakrishnan, PhD